CAR-T Cost in India

Different hospitals have different pricing policies when it comes to the cost of CAR-T in India. The top hospitals for CAR-T in India cover all the expenses related to the pre-surgery investigations of the candidate. Typically, the package cost of CAR-T in India includes the expenses related to the surgeon's fee, anesthesia, hospital, meals, nursing, and ICU stay. Many things may increase the cost of CAR-T in India, including prolonged hospital stays and complications after the procedure.

Therapy with chimeric antigen receptor (CAR) T cells is used to treat certain forms of blood cancer. Your cancer-fighting T cells are given a lab-made gene by scientists as part of the treatment. The alteration facilitates T cell cancer detection and elimination. When other therapies don't work or blood cancer returns, medical professionals may employ this one.

Blood cancer may occasionally be treated by CAR T-cell therapy. In some cases, it prolongs the survival of patients with certain blood malignancies.

Your immune system tracks proteins known as antigens on the surface of foreign cells to recognise them, including cancer.

• The proteins on the surface of your T cells are called receptors. These receptors are able to identify cells with aberrant antigens. T cells function as a watchdog for aberrant cells, activating upon detection of an aberrant cell by a receptor.
• After activating other immune system components to assist in locating and eliminating aberrant cells, the activated T cell proceeds to work, eliminating the aberrant cell.
• However, malignant cells are not always picked up by your T-cell receptors. Let me introduce you to CAR T cells—your T cells modified to identify a particular antigen on the surface of cancerous cells.
• By introducing a lab-made gene for a chimeric antigen receptor, scientists can alter your T cells. The newly created CAR T cells are then allowed to proliferate and expand until an adequate number exists to efficiently attack malignant cells.
• Once in your circulation, malignant cells are recognized and eliminated by CAR T-cell receptors. To ensure a steady supply of CAR T cells that specifically target your cancer cells, the cells also continue to proliferate. Because of this steady supply, scientists and medical professionals refer to CAR T-cell treatment as a kind of “living drug.”

Typical CAR-T treatment candidates include:

1. Patients diagnosed with specific blood malignancies, including follicular lymphoma, large B-cell lymphoma, acute lymphoblastic leukemia (ALL), Leukemia chronicocytic (CLL), etc.
2. Relapsed or Refractory Disease: People whose cancer reappears after first therapy or who don't react to conventional treatments.
3. Prior treatments: Individuals who are still undergoing treatment after undergoing several rounds of chemotherapy, targeted treatments, or stem cell transplants.
4. Health Status: Because CAR-T therapy can be intense and risky, candidates should generally be in good overall health and have a working organ system.
5. Age considerations: Although both adults and children have received CAR-T therapy, eligibility may be impacted by age depending on certain protocols and medical factors.

The main uses of CAR-T therapy are for the treatment of certain blood malignancies, such as:

• Acute Lymphoblastic Leukemia (ALL): Especially useful for patients in their teens and twenties who have not responded well to treatment or have relapsed.
• Diffuse large B-cell lymphoma (DLBCL) and other aggressive non-Hodgkin lymphoma types are included in the category of large B-cell lymphoma.
• Patients with Follicular Lymphoma: For those who have not responded to previous treatments.
• Patients with chronic lymphocytic leukemia (CLL): Applied to those who have not improved with conventional treatment.
• Multiple myeloma: Certain CAR-T treatments aim to specifically target proteins present on myeloma cells.

The usefulness of CAR-T therapy for solid tumors, such as pancreatic, prostate, and breast malignancies, is still being investigated, but these uses are still in the experimental stages. The efficacy of the therapy may differ depending on the particular cancer type and patient-specific circumstances.

Multiple possible side effects of CAR-T therapy exist, with varying degrees of severity. Among the most prevalent and important are:

1. The symptoms of cytokine release syndrome (CRS) include fever, lethargy, nausea, headaches, fast heartbeat, low blood pressure, and breathing difficulties. Serious complications may arise from severe cases.
2. Confusion, trouble speaking, seizures, tremors, and loss of coordination are examples of neurological toxicities. Days or weeks following treatment may see these side effects.
3. Infections: fever, chills, and indications of infection, like infusion site edema or redness.
4. Low blood counts are associated with fatigue, a higher chance of bruising or bleeding, and a higher risk of infection.
5. Excessive sensitivity Reactions include breathing difficulties, swelling, rashes, and itching.
6. Organ-Specific Toxicities: Vary depending on the organ, such as liver-related jaundice, kidney-related abnormalities in urine production, or lung-related shortness of breath.
7. Tumor Lysis Syndrome (TLS): Nausea, vomiting, fatigue, muscle cramps, and changes in heart rhythm
8. Fatigue and Malaise: Ongoing fatigue that may persist for some time.

A systemic inflammatory reaction known as cytokine release syndrome (CRS) can happen following specific immunotherapies, such as CAR-T treatment. It is caused by immune cells, especially T cells, being activated and proliferating and releasing a lot of cytokines, which are substances that help for managing immunological responses.

CAR-T cells target cancer cells upon recognition, which causes a rapid release of cytokines into the bloodstream, which subsequently causes CRS. The symptoms can vary in intensity and include the following:

• Fatigue and Fever
• Nausea
• Headache
• Joint and muscle soreness
• Rapid heart rate
• Low blood pressure
• Breathing difficulties

CRS is categorized into four degrees, from mild (grade 1) to severe (grade 4), according to its degree. Severe instances might need to be hospitalized and treated closely.

Yes, depending on the particular cancer kind, the patient's health, and the treatment plans, CAR-T therapy can be utilized in addition to other treatments. The following are some possible combinations of CAR-T therapy and other treatments:

1. Before Treatment Chemotherapy: To decrease the amount of lymphocytes already present and improve the conditions for the CAR-T cells to proliferate and perform as intended, some patients undergo chemotherapy before receiving CAR-T therapy.
2. Post-Treatment Therapies: To assist sustain remission or more specifically target any cancer cells that may still be present, post-CAR-T therapy may be combined with targeted or immunotherapies.
3. Combination with Other Immunotherapies: To increase overall efficacy, research is being conducted on the potential benefits of combining CAR-T therapy with other immunotherapies.

Healthcare professionals carefully assess patients and take into account several criteria, including patient health, prior treatments, and the kind of cancer, before deciding whether to combine CAR-T therapy with other treatments.

Your doctor might advise that you stay in the hospital right away following treatment because this treatment has the potential to cause major side effects. Your length of stay in the hospital could range from seven to ten days, depending on your condition and any adverse effects. For the first month following treatment, you should aim to live close to your treatment facility by car. Additionally, you'll need:

• Someone to watch over you around-the-clock in case side effects arise.
• Someone to drive you home for the first two months following the receipt of your T cells.

There are many hospitals that perform CAR-T in India. Some of the most renowned hospitals for CAR-T in India include the following:

1. Max Super Specialty Hospital, Vaishali
2. Max Super Speciality Hospital, Patparganj

After discharge from the hospital, the patient has to stay for another 30 days in the country for complete recovery. This time frame is important to ensure that the surgery was successful and the patient is fit to fly back.

Apart from the cost of CAR-T, the patient is also required to pay additionally for daily meals and guest house accommodation. These charges start from USD 50 per person.

Which are the best cities in India for CAR-T Procedure?

Some of the popular cities in India that offer CAR-T include the following:

• Noida
• Gurugram
• Mumbai
• Hyderabad
• Chennai
• Bangalore
• New Delhi

Many CAR-T surgeons offer video telemedicine consultations to patients who need this treatment. Some of them include the following:

The patient is supposed to stay at the hospital for about 2 days after CAR-T for monitoring and care. The patient is subjected to several biochemistry and radiological scans to see that everything is okay and the recovery is on track. After making sure that the patient is clinically stable, discharge is planned.

The average rating for CAR-T hospitals in India is 3.9. This rating is automatically calculated based on several parameters such as the infrastructure of the hospital, quality of services, nursing support, and other services.

There are more than 2 hospitals that offer CAR-T in India. The above-listed clinics are approved to perform the surgery and have the proper infrastructure to handle CAR-T patients. Additionally, these hospitals are known to comply with international standards as well as local legal requirements for the treatment of patients.